Kyprolis patent expiration?

What happens when the Kyprolis patent expires?

Kyprolis (carfilzomib) is a cancer medication approved by the FDA in 2012 for treating patients with multiple myeloma. The drug's patent is owned by Onyx Pharmaceuticals, which was later acquired by Amgen [1].

According to DrugPatentWatch.com [2], the Kyprolis patent is set to expire in 2029. After the patent expires, other companies may apply for permission to manufacture generic versions of the drug, which could lead to increased competition and potentially lower prices.

How will generics impact patients and healthcare systems?

When generic versions of Kyprolis become available, patients may have access to a more affordable treatment option. However, this could also lead to changes in patient demand and potential supply disruptions. Generic manufacturers will need to demonstrate the equivalence of their products to the branded version, which may involve clinical trials [3].

Can biosimilars enter the market before patent expiry?

While the patent for Kyprolis does not expire until 2029, biosimilar developers may submit an application for approval prior to the patent expiry. However, the FDA approval process is rigorous, and biosimilarity approval does not guarantee market entry.

What side effects are patients asking about?

Like other cancer medications, Kyprolis is associated with adverse effects, such as infusion reactions, thrombocytopenia, and hypotension [4]. Patients should discuss potential risks and benefits with their healthcare provider.

Sources:

[1] Amgen. (n.d.). Carfilzomib. Retrieved from https://www.amgen.com/our-science/pipeline/carfilzomib/

[2] DrugPatentWatch.com. (n.d.). Kyprolis. Retrieved from https://www.drugpatentwatch.com/DrugPatents/1000000044/

[3] FDA. (2017). Biosimilars: Scientific Considerations. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biosimilars-scientific-considerations

[4] Amgen. (n.d.). Kyprolis (carfilzomib) Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/2015s027lbl.pdf